The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
出版年份 2015 全文链接
标题
The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
作者
关键词
Multiple sclerosis, Meta-analysis, Database searching, Routes of administration, Systematic reviews, Publication ethics, Randomized controlled trials, Research reporting guidelines
出版物
PLoS One
Volume 10, Issue 12, Pages e0144538
出版商
Public Library of Science (PLoS)
发表日期
2015-12-09
DOI
10.1371/journal.pone.0144538
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
- (2015) Guillermo Izquierdo et al. Brain and Behavior
- Freedom from disease activity in multiple sclerosis
- (2015) E. Havrdova et al. NEUROLOGY
- The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
- (2015) Georgios Tsivgoulis et al. PLoS One
- Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations
- (2014) Mark S. Freedman et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
- (2013) Omar Khan et al. ANNALS OF NEUROLOGY
- Brain atrophy and lesion load predict long term disability in multiple sclerosis
- (2013) Veronica Popescu et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Progression in disability and regional grey matter atrophy in relapsing–remitting multiple sclerosis
- (2013) Louis Hofstetter et al. Multiple Sclerosis Journal
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
- (2013) Patrick Vermersch et al. Multiple Sclerosis Journal
- New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis
- (2012) Edward J. Fox et al. CURRENT OPINION IN NEUROLOGY
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome
- (2012) Claire Meyniel et al. PLoS One
- Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis
- (2011) J Theodore Phillips et al. Multiple Sclerosis Journal
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing—remitting multiple sclerosis
- (2010) Nicola De Stefano et al. Multiple Sclerosis Journal
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results
- (2009) G Giovannoni et al. Multiple Sclerosis Journal
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started